Categories: News Research

Test May Someday Connect Mesothelioma Patients to Ideal Treatments

A new test may someday be able to connect mesothelioma patients to an ideal treatment based on their tumor’s DNA. The Oncomine Dx Target Test was recently approved by the Food and Drug Administration (FDA) for non-small cell lung cancer (NSCLC). It can test a tissue sample for several types of cancer-causing mutations and identify treatments that target those mutations.

Connecting Patients to Targeted Therapies

Precision medicine is an innovative way of thinking for doctors. It involves personalizing treatment for each patient, including using their unique genetic profile to choose treatments. Targeted therapies are a common tool of precision medicine.

Unlike some traditional treatments, targeted therapies focus on specific biomarkers found in a tumor. Doctors use genomic testing, like the Oncomine Dx test, to figure out which treatment is best for each patient.

Targeted therapies have been popular in recent mesothelioma clinical trials and have shown a lot of promise. One example is Keytruda (pembrolizumab), a drug that works best for mesothelioma patients whose tumors express a protein called PD1. Using genomic testing, doctors can narrow down which patients will benefit from Keytruda.

Precision medicine allows doctors to use treatments that are most likely to work on their patients. However, since targeted therapies are specific to certain biomarkers, they won’t necessarily work on every patient. Testing is crucial to the success of precision medicine.

How the Oncomine Dx Target Test Works

The Oncomine Dx Target Test is the first test FDA approved to identify multiple mutations at once. The test was developed by Thermo Fisher Scientific Inc. to work with their Ion PGM Dx System, a device that analyzes DNA quicker and with smaller samples than traditional methods.

Doctors can take a small tumor tissue sample and run it through the Oncomine Dx test. The test reports on mutations to 23 different genes. 3 of these mutations have matching treatments for non-small cell lung cancer (NSCLC). Doctors can then prescribe the treatment that matches the genetic profile of their patient’s tumor. Hypothetically, Thermo Fisher will be able to add new mutations and treatments to their test as needed.

Without Oncomine Dx, doctors have to test for mutations separately and often have to try different treatments by trial and error.

Cancer patients don’t often have a lot of time to waste on treatments that don’t work. Oncomine Dx expedites the process of choosing the right treatment.

The Future of Mesothelioma Treatments

Many of the devices and treatments for lung cancers end up being tested for mesothelioma as well. The Oncomine Dx Target Test is an especially versatile test because it can test many different genes at once. It has the potential to work for many different cancers and even other diseases.

Not all treatments work for all mesothelioma patients.

The Oncomine Dx Target Test paired with targeted therapies could help doctors identify the most effective treatment for each patient.

This test could also tell doctors if chemotherapy will be effective on a certain patient. The standard treatment for mesothelioma patients is chemotherapy, but it’s not effective for all patients.

If the Oncomine Dx Target Test becomes available for more cancers, it could change the way doctors treat the disease. Mesothelioma patients may be able to live longer and healthier lives if they get the right treatment as soon as they are diagnosed.

Jamie Iovino

Jamie Iovino is the senior writer at Mesothelioma Guide. She creates and edits pages to make sure mesothelioma patients and their families receive the newest and most accurate information about mesothelioma.

Published by
Jamie Iovino
Tags: Clinical Trials News Research Treatment

Recent Posts

  • Clinical Trials
  • Mesothelioma Guide
  • Research

Is Combining Chemotherapy and Immunotherapy the Future of Mesothelioma Treatment?

For mesothelioma patients, treatment is often limited to three words: surgery, chemotherapy and radiation. Surgery is the optimal choice —…

9 hours ago
  • Advocacy
  • Mesothelioma Guide
  • News

EPA Officials Ignore Scientific Advice on Asbestos Ban

The Environmental Protection Agency (EPA) remains at the center of criticism regarding its handling of asbestos regulations. In April 2019,…

6 days ago
  • Advocacy
  • Mesothelioma Guide
  • News

New Jersey Bans Asbestos

The United States government has balked at the idea of a complete ban on asbestos, a dangerous, mesothelioma-causing mineral used…

1 week ago
  • Mesothelioma Guide
  • Treatment

11 Common Questions From Mesothelioma Caregivers

Much of the attention associated with mesothelioma goes to the person who has this rare and aggressive cancer. The patient…

2 weeks ago
  • Advocacy
  • Awareness
  • Diagnosis

You’ve Been Diagnosed With Mesothelioma: Now What?

Imagine this: You went to the doctor after experiencing symptoms you thought were signs of a common illness. Maybe you…

3 weeks ago
  • Cancer Centers
  • News
  • Prognosis
  • Treatment

Study Links Mesothelioma Survival to Size, Prestige of Medical Facility

A new study confirms the obvious link between mesothelioma treatment and survival length. However, the research’s primary revelation is that…

3 weeks ago